Andreas Wallnöfer is representing Angelini Investments on Nouscom’s Board of Directors. Andreas has over 30 years of experience in the pharmaceutical and biotech industry, spanning R&D leadership, venture capital, and biotech boards. He spent 12 years on F. Hoffmann-La Roche’s Pharma R&D Executive Leadership team and later became a Partner at BioMedPartners and Jeito Capital.
As an investor, board member, and operator, Andreas has helped develop numerous innovative biotech companies and contributed to several successful exits, including EyeBio’s acquisition by MSD in a deal valued at up to US$3 billion, just three years after the company’s inception.
At Roche, Andreas served as Head of Cardiovascular and Metabolism R&D, Global Head of Clinical Research and Exploratory Development, and a member of the Roche/Genentech Portfolio Committee. He also played a key role in integrating the Roche and Genentech clinical development organizations.
Today, Andreas serves as Chair or Board member of several biotech companies and advises Angelini Pharma and Angelini Holding on R&D and business development. He holds a Ph.D. in Pharmacology from the University of Basel and an Executive M.B.A. from IMD Lausanne.

